<DOC>
	<DOCNO>NCT02394340</DOCNO>
	<brief_summary>This open-label , maximal use study evaluate drug interaction potential luliconazole cream 1 % subject tinea pedis tinea cruris</brief_summary>
	<brief_title>Study Evaluating Drug Interaction Potential Luliconazole Cream 1 % Subjects With Tinea Pedis Tinea Cruris</brief_title>
	<detailed_description />
	<mesh_term>Tinea</mesh_term>
	<mesh_term>Tinea Pedis</mesh_term>
	<mesh_term>Omeprazole</mesh_term>
	<criteria>Subjects clinical diagnosis moderate severe interdigital tinea pedis , define PGA score 2 3 foot , AND moderate severe tinea cruris , define PGA score 2 3 Subjects mycological diagnosis tinea pedis AND tinea cruris confirm detection fungal hypha microscopic KOH wet mount Subjects must good general health free disease might interfere study evaluation Subjects ability willingness follow study procedure , attend schedule visit successfully complete study Female subject pregnant and/or nurse plan pregnancy course trial Subjects immunocompromised Subjects recent history currently know drug alcohol abuse Subjects history intolerance hypersensitivity imidazole compound , proton pump inhibitor inactive component Luliconazole Cream 1 % omeprazole Subjects lifethreatening condition within last 6 month Subjects uncontrolled diabetes mellitus Subjects unable communicate cooperate investigator Subjects use medication treatment tinea pedis and/or tinea cruris ( see investigator length time prior study start ) Subjects receive concomitant drug know inhibit and/or induce CYP2C19 and/or CYP3A4 ; interact omeprazole Because potential drug interaction luliconazole , administration medication know substrate CYP3A4 , CYP2B6 , CYP2C8 CYP2C19 carefully monitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>